QTTB · XBRL financial data
Q32 Bio financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (QTTB's year ends in late December)
- † Share count changed about 1/5 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal quarters (QTTB's year ends in late December)
- † Share count changed about 1/5 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal quarters (QTTB's year ends in late December)
| In thousands of dollars | Dec 31, 2023 | †Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jul 16, 2026 | Sep 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | (16,119)* | 1,029 | (16,978) | (17,595) | (14,189)* | (11,031) | (9,489) | (7,389) | 57,730* | (7,609) | — | (8,922) |
| Stock-based compensation | 847* | 417 | 1,336* | 1,382* | 1,251* | 1,342 | 1,268* | 1,176* | 1,469* | 1,548 | — | 2,900* |
| Net cash from operating activities | (21,575)* | (14,551) | (22,214)* | (19,522)* | (11,428)* | (12,482) | (10,651)* | (4,230)* | (6,180)* | (6,343) | — | (4,418)* |
| Purchases of property and equipment | 0* | 0 | 15* | 58* | 2* | — | — | 0* | 0* | — | — | — |
| Net cash from investing activities | 31,716* | 97 | 9,888* | 9,942* | (2)* | 0 | 0* | 0* | 7,000* | 0 | — | (52)* |
| Proceeds from issuing common stock | 0* | 42,000 | 0* | 0* | 0* | 0 | 0* | 0* | 0* | 10,360 | — | 0* |
| Net cash from financing activities | 14* | 99,346 | (5,522)* | 997* | 317* | — | — | (1,563)* | (1,562)* | 8,797 | — | 187,787* |
| Net change in cash | 10,155* | — | — | — | — | — | — | — | — | — | — | — |
- † Share count changed about 1/5 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Q32 Bio | 289,587 | not reported | (4,418)* | 29.9M | 62.5 quarters | 10-QSep 30, 2026 |
| Kiora Pharmaceuticals | 7,077 | not reported | (1,892)* | 4.4M | 8.9 quarters | 10-QJun 30, 2026 |
| Brainstorm Cell Therapeutics | 22 | not reported | (895) | 11.0M | 0.0 quarters | 10-QJun 30, 2026 |
| Scienture Holdings | 8,188 | 344 | (3,132)* | 41.1M | 2.6 quarters | 10-QJun 30, 2026 |
| LeonaBio | 32,323 | not reported | (16,958)* | 9.4M | 3.0 quarters | 10-QJun 30, 2026 |
| Mannatech | 6,034 | 26,650 | (792)* | 1.9M | 7.6 quarters | 10-QJun 30, 2026 |
| Traws Pharma | 5,016 | not reported | (7,504)* | 15.4M | 0.7 quarters | 10-QJun 30, 2026 |
| BioCardia | 4,117 | not reported | (1,735)* | 15.1M | 2.4 quarters | 10-QJun 30, 2026 |
| Phio Pharmaceuticals | 12,996 | not reported | (4,035)* | 11.6M | 3.2 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.
